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EVIDENCE BASED NEURO-ONCOLOGY
Role of palliative CSF diversion in patients with intracranial metastatic disease
and symptomatic hydrocephalus
Farhan A. Mirza,1 Muhammad Shahzad Shamim2

Abstract
Hydrocephalus, unless treated, is one of the terminal
manifestations of intracranial metastatic disease. Single
lesions causing obstructive hydrocephalus are amenable
to surgical resection, but in the setting of multiple lesions
and communicating hydrocephalus from leptomeningeal
disease, the approach to treatment is much less defined.
The use of endoscopic third ventriculostomy (ETV) and
ventriculoperitoneal shunting (VPS) has been described,
but data is limited. In this review, we summarize the
sparse data available in literature describing the use of
CSF diversion for patients with metastatic disease
presenting with hydrocephalus and neurological decline.
Keywords: Metastatic tumours, hydrocephalus,
endoscopic third ventriculostomy, ventriculoperitoneal
shunt, CSF diversion

Background
Treatment of cancers in the form of surgery,
chemotherapy, and radiation therapy in general has been
improving, resulting in improved survival of these
patients. With longer survival, tumour recurrence and
metastasis are being seen more often. It is estimated that
25-30% of cancer patients develop brain metastases. In
intracranial metastatic disease, especially in the presence
of multiple lesions or leptomeningeal spread, the
prognosis is usually considered poor on the scale of few
weeks to months.1 In certain situations however, if there is
a single lesion or a posterior fossa periventricular lesions
resulting in obstructive hydrocephalus, primary surgical
resection can be of benefit in relieving this obstruction
and provide survival benefit.1
The role of palliative CSF diversionary procedures for this
situation is less well defined. Limited data exists in
literature describing the use of ventriculoperitoneal shunt
or endoscopic third ventriculostomy as a CSF diversion
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method for obstructive hydrocephalus.2-5 Reports are also
present on communicating hydrocephalus in the setting
of leptomeningeal disease and high grade gliomas.4-7
Lumboperitoneal shunting has also been described.8

Review of Evidence
Ventriculoperitoneal Shunt (VPS)
In 2015, Nigim et al., published their series of 59 patients
who underwent VPS placement for hydrocephalus in the
background of brain tumours.4 Forty patients with
metastatic lesions and 19 with primary brain neoplasms
were included. Nineteen patients had obstructive and 40
patients had communicating hydrocephalus. Eighty-three
percent of patients in Nigim's series had progressive
systemic disease. Ninety-three percent patients showed
improvement in their symptoms and shunt related
complications were noted in 11.9%. The authors did not
comment on outcomes with respect to the type of
hydrocephalus (obstructive vs. communicating), thus it is
difficult to generalize their results to either scenario.
Overall good outcomes with good shunt patency were
noted at six months and one year.4
Prior to this series, Lee et al., described their experience
with 50 patients in 2011.5 Ten of these had parenchymal
lesions and the rest presented with leptomeningeal
disease with or without parenchymal lesions. Thirteen
patients had obstructive and 37 had communicating
hydrocephalus. Overall 80% patients noted improvement
in headache, nausea, and cognitive status and 10%
complication rate was noted, including one death from
intracerebral haemorrhage. One of the interesting
findings reported was the presence of opening pressure
of >30 cm H2O as an independent risk factor for poorer
outcomes. It was also reported that patients who
underwent VPS followed by therapy for their systemic
disease had better outcomes. This however was
attributed to patient selection. It is also interesting to note
that six patients in their series with primarily
leptomeningeal spread had a survival period of over one
year after VPS placement. Their data supports the
utilization of CSF diversion even in cases of
leptomeningeal disease which is usually considered as an
end stage manifestation.
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Figure-1 (a,b,c): MRI Brain T2 axial, Flair axial and T! coronal with contrast images showing GBM with hydrocephalus.

Figure-2 (a,b,c): CT Brain axial plain showing multiple metastases from a primary lung cancer, and obstructive hydrocepahalus due to obstruction of fourth ventricle.

Endoscopic Third Ventriculostomy (ETV)
Third ventriculostomy serves as a physiologic shunt can
be performed endoscopically using anatomic landmarks,
or with stereotaxis using image guidance. ETV mitigates
the complications that may accompany shunt placement
such as hardware malfunction, wound breakdown over
shunt hardware, over-drainage, and possible seeding of
the peritoneal cavity. It also avoids the discomfort caused
by subcutaneous tunneling of the shunt. However, it may
not be applicable for all patients with hydrocephalus and
the ETV Success Score may be used to predict which

patients are more likely to benefit from it, and which are
best treated with a VPS.9
Only two reports are present in literature regarding the
use of ETV for hydrocephalus in metastatic disease.
Nguyen et al., in 1999 presented their case series of seven
patients with metastatic lesions to the thalamus or
posterior fossa resulting in CSF obstruction.2 Five of these
cases showed improvement after ETV.One patient
proceeded to comfort care after no improvement. One
patient had post-operative improvement but returned in
a few days with worsening hydrocephalus, and required
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VPS with resolution of symptoms.
To further this, Chen et al., published their results of 16
patients in 2011.3 All patients in their series had failed
chemotherapy, had active primary disease, and had low
KPS scores. All patients had imaging findings consistent
with obstructive hydrocephalus from metastatic lesions.
Symptomatic improvement was observed after palliative
ETV in 11 patients (69%). Four (25%) were deceased by the
end of the first month. This improvement is comparable
with that reported for the use of VP shunts.
Although the data on this topic is insufficient to draw
conclusions, CSF diversion appears as a reasonable choice
for certain patient subgroups with symptomatic
hydrocephalus and intracranial metastatic disease. One
cannot over emphadize the use of Karnofsky Performance
Scale (KPS) when approaching patients as it appears to
have direct impact on survival. Younger age, better
neurocognitive status, more limited extent of systemic
disease and responsiveness to treatment should also be
factored into the equation.In choosing surgical modality,
results from the ETV and VPS series are comparable, with
a lower rate of complications with ETV. It would be
reasonable to use ETV as the first line treatment,
specifically in obstructive hydrocephalus cases, with
predictive success scores in the realm of 70-90% as
predicted by the ETV Success Score.

Conclusion
Surgical CSF diversion for hydrocephalus in intracranial
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metastatic disease is a viable option in symptomatic
patients. It has been shown to improve symptoms and
although the existing data is sparse, it does also support
improved survival in select cases.
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